Sanofi Gets A Helping Hand From US FDA At Dengvaxia Review

 
• By Sue Sutter

After split verdicts on efficacy and safety for Sanofi’s proposed population for the dengue vaccine, FDA added two new questions limited to pediatric use, which drew strong advisory committee support.

Safety equipment, Life buoy or rescue buoy floating on sea to rescue people from drowning man.
FDA threw Sanofi a proverbial life preserver in the form of two additional voting questions on effectiveness and safety for a pediatric population.

More from US FDA Performance Tracker

More from Regulatory Trackers